PharmiWeb.com - Global Pharma News & Resources
07-May-2024

Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024

Fresenius SE & Co. KGaA / Key word(s): Change in Forecast
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024

07-May-2024 / 21:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024.

Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%).

The increase of the group outlook is based on improved business prospects for Fresenius Kabi. Fresenius Kabi now expects organic revenue growth in the mid to high single-digit percentage range for fiscal year 2024 (previously: mid single-digit percentage range). The EBIT margin is now expected to range between 15 and 16% (previously: around 15%).

The adjustment of the group outlook also reflects the fact that the forecast is now provided without Fresenius Vamed, i.e. exclusively for the operating companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed’s rehabilitation business, Fresenius has initiated its structured exit from its investment company Fresenius Vamed.



For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.


Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., May 7, 2024

----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------

End of Note

 

End of Inside Information

07-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1898031

 
End of Announcement EQS News Service

Editor Details

Last Updated: 07-May-2024